Suppose this should technically go under this thread.J&J...

Suppose this should technically go under this thread.

J&J partnered with Legend Biotech in an autologous CAR T-cell therapy for melanoma cancers, not dissimilar to OCC's ATI in taking patients cells, cultivating for 4 weeks and then infusing, in a now $500 million deal. That deal went from FDA approval in Feb 2022 to $55 million in quarterly sales by September (many investors were concerned on the timescales and IP of OCC in ATI)

https://www.fiercepharma.com/pharma/carvyktis-growth-sanofi-jj-sell-plants-lg-chems-aveo-buy

"Johnson & Johnson and Legend Biotech’s CAR-T therapy Carvykti racked up $55 million in third-quarter sales. That was up from $24 million in the three months ended in June, the first full quarter it was on the market. The companies are currently working to ramp up manufacturing capacity in anticipation of a year-end phase 3 readout in multiple myeloma patients who had failed one to three prior lines of therapy."

J&J are pegging $5 billion in future sales and Legend BioTech is now a $8 billion USD company by the way:

https://www.fiercepharma.com/pharma/johnson-johnson-legend-car-t-cilta-cel-myeloma-ring-fda-approval-rivaling-bristol-myers

(just a little insight of the potential IF a J&J deal goes through on ATI)